Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275708 | 1.00 | FFAR3 (0.39) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| SCHEMBL369709 | 1.00 | FFAR3 (0.39) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| Hydrochloric Acid SCHEMBL19022235 | 0.98 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL19022236 | 0.98 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL17171332 | 0.93 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL17157178 | 0.93 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL27092759 | 0.91 | FFAR3 (0.36) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL28616020 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL11303377 | 0.84 | FFAR3 (0.40) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11303374 | 0.84 | FFAR3 (0.40) | FFAR3TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127559-A1 | PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEIN | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-27 | — | — | US | claimed |
| CN-115942948-A | Peptide compounds and methods of treating diseases | 免疫制药有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20230049549-A1 | PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME | IMMUNITY PHARMA LTD. (IL) | 2023-02-16 | — | — | US | claimed |
| EP-4121441-A1 | PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 PROTEIN | Yeda Research and Development Co. Ltd (IL) | 2023-01-25 | — | — | EP | claimed |
| WO-2021144798-A1 | PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME | IMMUNITY PHARMA LTD. (IL) | 2021-07-22 | — | — | WO | claimed |
| CN-110314125-B | Environment-friendly wet tissue for infants and preparation method thereof | 惠好医疗科技(浙江)有限公司 | 2020-11-20 | — | — | CN | claimed |
| CN-107412867-B | Preparation method of heterogenous acellular dermal matrix | 广州润虹医药科技股份有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-110314125-A | A kind of infant's environment-friendly type wet tissue and preparation method thereof | 吴宝琴 | 2019-10-11 | — | — | CN | claimed |
| CN-106176291-A | Hand-mouth baby wet tissue compositional liquor and wet tissue | 金红叶纸业集团有限公司 | 2016-12-07 | — | — | CN | claimed |
| US-20140242100-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-1612722-A | Compositions comprising enzymes stabilized with certain osmoprotectants and methods of using such compositions for personal care | PROCTER & GAMBLE (US) | 2005-05-04 | — | — | CN | claimed |
| EP-1446090-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| EP-1446096-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILISED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | THE PROCTER & GAMBLE COMPANY | 2003-09-18 | — | — | US | claimed |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | THE PROCTOR & GAMBLE COMPANY | 2003-08-21 | — | — | US | claimed |
| WO-2003041680-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003041667-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| EP-0422937-B1 | Fibrinogen receptor antagonists | MERCK & CO INC (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1993000108-A1 | NOVEL INHIBITORS OF PLATELET AGGREGATION | CORVAS INTERNATIONAL, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0422937-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1991-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | TREH, CUTA, LPO | FFAR3 3574/4885TSHR 3649/4885NFKB1 2110/4885 |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | CUTA, LCT, TYR | FFAR3 4211/4885TSHR 4356/4885NFKB1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.